Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
Amanda L McDonell,1 Urpo Kiiskinen,2 Danielle C Zammit,3 Robert W Kotchie,1 Per-Olof Thuresson,3 Claudia Nicolay,4 Thomas Haslam,1 Michiel Bruinsma,5 Anne-Jeanine Janszen-Van Oosterhout,6 Thorsten Otto41IMS Health, London, UK; 2Eli Lilly and Company, Helsinki, Finland; 3IMS Health, Basel, Switzerlan...
Main Authors: | McDonell AL, Kiiskinen U, Zammit DC, Kotchie RW, Thuresson PO, Nicolay C, Haslam T, Bruinsma M, Janszen-Van Oosterhout AJ, Otto T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-01-01
|
Series: | ClinicoEconomics and Outcomes Research |
Online Access: | http://www.dovepress.com/estimating-the-real-world-daily-usage-and-cost-for-exenatide-twice-dai-peer-reviewed-article-CEOR |
Similar Items
-
Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
by: Yuusuke Watanabe, et al.
Published: (2020-03-01) -
Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus
by: Jie Zhang, et al.
Published: (2022-01-01) -
Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
by: Chiquette E, et al.
Published: (2012-11-01) -
The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
by: Bruce Wang, et al.
Published: (2015-01-01) -
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
by: Ostenson CG, et al.
Published: (2013-04-01)